瑞舒伐他汀钙对不稳定型心绞痛患者血清淀粉样蛋白A及单核细胞趋化蛋白-1的影响

Affection of Rosuvastatin Calcium on SAA and MCP-1 in Patients with Unstable Angina Pectoris

目的:观察不同剂量瑞舒伐他汀钙对冠心病患者血清淀粉样蛋白A(SAA)及单核细胞趋化蛋白-1(MCP-1)的影响。方法:选取不稳定心绞痛患者62例,年龄(52.8±2.6)岁,按随机数字表法分为A组(瑞舒伐他汀钙20 mg)和B组(瑞舒伐他汀钙10 mg),每组31例,治疗6周。检测患者治疗前后的血液生化指标、SAA及MCP-1并进行比较。结果:治疗后两组的SAA、MCP-1、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和甘油三酯(TG)较治疗前水平均降低(P<0.05),A组较B组降低更明显(P<0.05);两组高密度脂蛋白胆固醇(HDL-C)较治疗前均升高(P<0.05),A组较B组升高更明显(P<0.05)。结论:相对较高剂量的瑞舒伐他汀钙可更好地降低冠心病患者SAA及MCP-1水平,发挥其对抗动脉粥样硬化、稳定粥样硬化斑块、降低心血管事件等方面的重要作用。

Objective：To observe the effect of different doses Rosuvastatin Calcium on SAA and MCP-1 in patients with unstable angina pectoris.Method：62 patients with unstable angina, age（52.8±2.6） years were selected and divided into the group A（Rosuvastatin calcium 20 mg） and the group B（Rosuvastatin calcium 10 mg） according to random number table method, 31 cases in each group, treatment for 6 weeks. Before and after treatment, the blood biochemical, SAA and MCP-1 of the two groups were detected and compared.Result：After treatment, The serum levels of SAA, MCP-1, TC, LDL–C of two groups were decreased than before treatment（P〈0.05）, the group A were significantly decreased than the group B（P〈0.05）; the HDL–C of two groups was higher than before treatment（P〈0.05）, the group A was higher than the group B（P〈0.05）.Conclusion：Rosuvastatin calcium with high dose can better reduce SAA and MCP-1 levels in patients with stable angina pectoris, it playing an important role in terms of against atherosclerosis, stability of atherosclerotic plaques, and to reduce the cardiovascular events.